CM
BEAM icon

Crestline Management’s Beam Therapeutics BEAM Stock Holding History

Crestline Management’s Portfolio BEAM Stock Details BEAM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-62,969
Closed -$1.56M – 76
2024
Q4 		$1.56M Buy
62,969
+45,554
+262% +$1.16M 0.05% 329
2024
Q3 		$427K Buy
+17,415
New +$450K 0.02% 399

Other funds holding BEAM

FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Crestline Management's BEAM Position: Q1 2025 in Review

Crestline Management sold out of Beam Therapeutics (BEAM) in Q1 2025, closing a stake of 62,969 shares — an estimated $1.56M sold.

Crestline Management first reported a position in BEAM in Q3 2024 and held it in 2 quarters. The position peaked at $1.56M in Q4 2024. 238 funds tracked by Wall St. Rank hold BEAM as of Q1 2025.

  • Crestline Management reported no remaining Beam Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Crestline Management sold 62,969 Beam Therapeutics shares in Q1 2025, an estimated $1.56M.
  • Crestline Management first reported a position in Beam Therapeutics in Q3 2024 and held it in 2 quarters.
  • Crestline Management's Beam Therapeutics position peaked at $1.56M in Q4 2024.
  • 238 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2025.

Based on Crestline Management's 13F filing for Q1 2025, filed 15 May 2025.